Slides
Page 1
Earnings call Interim Report July – September 2026 23 October 2 02 6 Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved
Page 2
Acting CEO & CTO Chief Financial Officer & Head of Investor Relations Mikael Kågebäck Elisabeth Hedman 2Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved Agenda 01 This is Sleep Cycle 02 Sleep Cycle & Audiowell 03 Financial Development Presenters 04 Summary and Q&A
Page 3
Our mission is to improve global health by empowering people to take control of their sleep. 3Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved
Page 4
4 Built largely through organic growth and with a highly efficient operating model Sleep Cycle’s mission is to improve global health by helping people sleep better The world’s leading sleep tracking and analysis platform Scalable business model with recurring revenue 2.5m Yearly active users1) +60 Scientifically based sleep programs +4bn Nights analyzed +82m Installs2) Note(s): 1) Active users 2025. Defined as individuals w ith an activity in the app during the past year. 2) Up until Dec. 2025. Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved A uniquely scaled sleep platform Data, distribution and sleep expertise built over more than a decade. Difficult to replicate in a single platform.
Page 5
5Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved There is a growing recognition of sleep as a critical component of overall health, with insufficient sleep linked to various chronic conditions such as obesity, diabetes, and cardiovascular diseases Sleep is moving beyond the sleep app category Growing relevance Sleep is increasingly recognized as a key driver of health, recovery, performance and longevity. Technology fit Demand is increasing for passive, continuous and embedded health insights — exactly where Sleep Cycle’s technology is strongest. New ecosystems Sleep experiences are moving into wearables, pharma, digital health, smart home and broader health platforms.
Page 6
6Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved One platform, three businesses: B2B now 20% of revenue P I L L A R 1 · B 2 C Sleep Cycle App Sleep tracking, smart alarm, Sleep Aid and the AI sleep coach Luma. 1.4m MAU 0.8m daily active users · Q3 average 605k paying subscribers P I L L A R 2 · B 2 C / B2 B Apnea Alert Contactless sleep apnea risk check after one night with the phone. Early 2027 Class I launch in the EU and UK 150k+ registered interest P I L L A R 3 · B 2 B Tech Licensing SDK that brings Sleep Cycle analysis into partner apps and hardware. 3 customers Fastest-growing part of B2B Moera · Ant Group · Ultrahuman S H A R E D T E C H N O L O G Y P L A T F O RM Patented sound-based AI · 4bn+ nights analysed · sleep, breathing and cough · only a microphone needed
Page 7
7Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved Sleep Cycle App: ARPU up, conversion is the priority 605k B2C subscribers (792k) −24% y/y 282 SEK FX-adj. ARPU (276) +2% y/y 1.4m Monthly active users 0.8m DAU Q 3 I N BR I E F Pricing Price increases lifted ARPU but weighed on new-subscriber conversion Renewals Stable renewal rate Acquisition New sales in the App Store remain weak P R I O RI T Y A H E A D Rebuild conversion New onboarding: value from the first night New paywalls and win -back of former subscribers App adapted to the new iOS and Apple devices
Page 8
Planned launch in the EU and UK in early 2027 as a Class I medical device
Page 9
9Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved Apnea Alert launches early 2027; 150k+ signed up ~1bn people with sleep apnea worldwide ~SEK 25bn estimated addressable market ~80% have no diagnosis ~20% diagnosed S L E E P L A B Polysomnography Referral, sensors overnight and long waiting lists. Hard to scale. W E A R A BL E S Watches and rings Reach only people who already own and wear the device. S L E E P C Y C L E Apnea Alert One night with an iPhone on the bedside table gives a risk assessment. L A U N C H P L A N Early 2027 Class I launch in the EU and the UK Next step Class IIa in the EU and FDA submission in the US
Page 10
Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved Tech Licensing: our sleep analysis inside partners’ products 10 W H A T I T I S Sleep Cycle’s sleep analysis, licensed as an SDK Partners build contactless sleep measurement into their own products. 4B+ nights of real-world data 1 mic no wearable needed Patented also in the app and Apnea Alert P A R T N E R S A D D E D I N Q 3 W EA RA BL ES Ultrahuman Pilot became an SDK licence DI GITA L H EA LT H Ant Group Tech licence; entry into China S MA RT HO ME & I OT Moera Runs on the mattress itself P U BLIC HEA LTH UKHSA Pilot: early flu and COVID signal Commercial deal under discussion
Page 11
11Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved A leaner, AI-first organisation, ready for the next chapter In September we introduced a more AI-driven way of working, with fewer decision levels and smaller teams that own their results. The aim: run our business areas faster and more efficiently , with lower overhead. W H A T C H A N G E S 1 AI first AI is built into how we develop, analyse and operate, not added on top. 2 Broader roles Fewer , broader roles. Small teams own their results end to end. 3 Faster decisions Fewer decision levels, so decisions are made close to the work. W H A T W E G A I N ~35 MSEK annual savings, with a large effect already in Q4 ~15 roles affected, and several consultant assignments ended Faster development delivery, with first results visible R E A D Y F O R T H E N E X T C H A P T E R Slimmer, more focused, and with a clearer path to profitable growth. Savings and affected roles as reported. Source: Sleep Cycle interim report Q3 2026.
Page 12
12Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved Proposed acquisition of Audiowell Sleep Cycle’s sleep analysis combined with Audiowell’s catalogue of sleep and relaxation music. Audiowell CEO Gustav Forssell is intended as Group CEO. Paid in new shares · EGM vote 11 November · closing expected Q4 2026 N E T S A L E S A N D E B I T 2 0 2 5 W H Y C O M B I N E Net sales EBIT Margin Sleep Cycle 248 MSEK 66 MSEK 27% Audiowell¹ 378 MSEK 216 MSEK 57% Combined² 625 MSEK 282 MSEK 45% • Wellness focus: from sleep to well-being • More revenue streams: apps, streaming, white-label • Faster launches: content tailored to each user 1) Illustrative, K3, not audited. 2) Simple sum. Completion also requires FDI approval.
Page 13
Top line still pressured by lower consumer acquisition and FX. Reported EBIT burdened by items affecting comparability of 14.0 MSEK related to the CEO change and the reorganisation. 50.9 Net sales, MSEK · -17.3% (-12.4% FX adj.) 1.1 EBIT, MSEK · 2.2% margin (27.3%) 15.1 Adj. EBIT, MSEK · 29.7% margin (27.3%) B2B share of revenue, Q2'24–Q3'26 13Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved 631k Paying subscribers · 832k LY 262 SEK ARPU · 269 LY · FX -adj. 282 (269) 75.2 MSEK Liquidity, MSEK · 114.6 LY Q3: record B2B, a leaner organisation and adjusted EBIT margin of 29.7% 36 Average no. of employees Q3'26 5.4% 19.7%
Page 14
14 E B I T , r e p o r t e d 1.1 MSEK · 2.2% margin I t e m s a f f e c t i n g c o m p a r a b i l i t y 14.0 13.7 CEO change & reorg. · 0.3 public offer A d j u s t e d E B I T 15.1 29.7% margin (27.3% in Q3 2025) Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved One-offs of 14.0 MSEK; adjusted EBIT 15.1 MSEK 1.1 EBIT, reported +13.7 CEO change & reorganisation +0.3 Public offer costs 15.1 Adjusted EBIT Mainly CEO change and reorganisation costs. Capitalised development of 10.4 MSEK (2.6) is not expensed and lifts the 29.7% adjusted margin.
Page 15
Financial performance – Q3 2026 15Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved • FX-adjusted net sales growth of -12.4%, driven by lower new B2C sales in the App Store. • B2B revenue growth was +49.2% , now 19.7% of total revenue (10.9%), of which SEK 9.8m recurring. • Personnel expenses of 24.7 include 13.4 of items affecting comparability. Adjusted personnel expenses were 11.2 (13.8), -19%. • Other external expenses of 16.2 include 0.5 of items affecting comparability. Adjusted: 15.7 (17.0), -8%. • EBIT-margin of 2.2% for Q3; adjusted EBIT -margin of 29.7% (27.3%). • Items affecting comparability of 14.0 MSEK — SEK 13.7m for the CEO change and reorganisation and SEK 0.3m for the public offer. SEK M Q3-26 Q3-25 CHANGE Net sales 50.9 61.5 -17.3% Other operating income 0.4 0.0 Capitalized work for own account 1.1 0.8 35% Distribution costs -8.4 -12.4 -32% Other external expenses -16.2 -17.0 -5% Personnel expenses -24.7 -13.8 79% Other operating expenses -0.3 -0.6 -45% EBITDA 2.7 18.5 -15.9 EBITDA-margin 5.2% 30.1% D&A -1.5 -1.7 -13% EBIT 1.1 16.8 -15.7 EBIT-margin 2.2% 27.3% Items affecting comparability 14.0 — Adjusted EBITDA 16.6 18.5 -1.9 Adjusted EBITDA-margin 32.7% 30.1% Adjusted EBIT 15.1 16.8 -1.7 Adjusted EBIT-margin 29.7% 27.3%
Page 16
Financial performance – Jan–Sep 2026 16Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved • FX-adjusted net sales growth of -13.7%, driven by lower new B2C sales in the App Store. • B2B revenue grew +39.8% to 25.2 MSEK, 16.4% of net sales (9.5%). • Personnel expenses of 59.6 include 15.7 of items affecting comparability. Adjusted personnel expenses were 43.9 (41.2), +7%. • Other external expenses of 65.9 include 9.2 of items affecting comparability. Adjusted: 56.8 (51.0), +11%. • EBIT-margin of 0.2%; adjusted EBIT -margin of 16.4% (27.3%). • Items affecting comparability of 24.9 MSEK: 15.7 for the CEO change and reorganisations, 9.2 mainly for the public offer. • Capitalised development of 34.6 MSEK (9.3), mainly sleep apnea and the SDK. SEK M Jan–Sep 26 Jan–Sep 25 CHANGE Net sales 153.3 190.0 -19.3% Other operating income 2.0 0.3 Capitalized work for own account 3.9 2.1 86% Distribution costs -27.0 -39.6 -32% Other external expenses -65.9 -51.0 29% Personnel expenses -59.6 -41.2 45% Other operating expenses -1.8 -4.2 -57% EBITDA 4.9 56.3 -51.4 EBITDA-margin 3.2% 29.6% D&A -4.5 -4.4 4% EBIT 0.3 51.9 -51.6 EBIT-margin 0.2% 27.3% Items affecting comparability 24.9 — Adjusted EBITDA 29.8 56.3 -26.5 Adjusted EBITDA-margin 19.4% 29.6% Adjusted EBIT 25.2 51.9 -26.7 Adjusted EBIT-margin 16.4% 27.3%
Page 17
17Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved 26.3% 28.3% 27.3% 24.3% 12.8% 6.8% 29.7% ~20% Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 FY26e Adjusted EBIT margin per quarter and FY2026 outlook Q3 lifted by lower marketing and consultancy costs and record B2B revenue. Reaching ~20% for FY2026 implies ~30% in Q4 (16.4% YTD). O U T L O O K 2 0 2 6 · C U R R E N T B U S I N E S S A D J U S T E D E B I T M A R G I N ~20% for FY2026 Expected with the new organisation in place. R E P O R T E D E B I T M A R G I N ~7% for FY2026 Incl. items affecting comparability of ~25 MSEK YTD (public offer, CEO change, reorganisation). C OS T B A S E ~35 MSEK annual savings Substantial effect in Q4, full effect from 1 January 2027. Outlook excludes effects of the proposed Audiowell acquisition. Outlook 2026: ~20% adjusted EBIT margin for full year
Page 18
Questions & Answers 18Sleep Cycle © 2026 Sleep Cycle AB. All Rights Reserved